Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 11/20 | 1.00 |
| ▸ | MAP3K7 | O43318 | 8/20 | 1.00 |
| ▸ | MAP4K2 | Q12851 | 8/20 | 1.00 |
| ▸ | MAP3K20 | Q9NYL2 | 7/20 | 1.00 |
| ▸ | CSK | P41240 | 5/20 | 1.00 |
| ▸ | EPHA2 | P29317 | 3/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 2/20 | 1.00 |
| ▸ | ABL1 | P00519 | 2/20 | 1.00 |
| ▸ | RAF1 | P04049 | 2/20 | 1.00 |
| ▸ | LYN | P07948 | 2/20 | 1.00 |
| ▸ | SRC | P12931 | 2/20 | 1.00 |
| ▸ | EPHB2 | P29323 | 2/20 | 1.00 |
| ▸ | ABL2 | P42684 | 2/20 | 1.00 |
| ▸ | EPHB4 | P54760 | 2/20 | 1.00 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.74 |
| ▸ | FES | P07332 | 1/20 | 0.67 |
| ▸ | FER | P16591 | 1/20 | 0.67 |
| ▸ | FLT3 | P36888 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29725987 | 1.00 | MAPK14 (1.00) | MAPK14MAP3K7MAP4K2MAP3K20CSK | |
| SCHEMBL2284510 | 1.00 | MAPK14 (1.00) | MAPK14MAP3K7MAP4K2MAP3K20CSK | |
| SCHEMBL16786132 | 0.97 | MAPK14 (0.95) | MAPK14MAP3K7MAP4K2MAP3K20CSK | |
| SCHEMBL29496497 | 0.91 | MAPK14 (0.83) | MAPK14MAP3K7MAP4K2MAP3K20CSK | |
| SCHEMBL2284678 | 0.91 | MAPK14 (0.83) | MAPK14MAP3K7MAP4K2MAP3K20CSK | |
| SCHEMBL2284669 | 0.91 | MAPK14 (0.83) | MAPK14MAP3K7MAP4K2MAP3K20CSK | |
| SCHEMBL19986848 | 0.88 | MAPK14 (1.00) | MAPK14MAP3K7MAP4K2MAP3K20CSK | |
| SCHEMBL26882912 | 0.87 | MAPK14 (0.77) | MAPK14MAP3K7MAP4K2MAP3K20CSK | |
| SCHEMBL14704592 | 0.87 | MAPK14 (0.78) | MAPK14MAP3K7MAP4K2MAP3K20CSK | |
| SCHEMBL17515255 | 0.86 | DDR1 (0.95) | MAPK14MAP3K7MAP4K2MAP3K20CSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2519517-B1 | TYPE II RAF KINASE INHIBITORS | DANA FARBER CANCER INST INC (US) | 2015-03-25 | — | — | EP | claimed |
| US-11826365-B2 | Type II raf kinase inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11459570-B2 | Transgenic mouse expressing amyloid precursor protein that has olfactory neuron degeneration | THE GENERAL HOSPITAL CORPORATION (US) | 2022-10-04 | — | — | US | disclosed |
| US-20200297721-A1 | TYPE II RAF KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-09-24 | — | — | US | disclosed |
| US-20190352643-A1 | METHODS FOR TREATING NEURODEGENERATIVE DISEASES | THE GENERAL HOSPITAL CORPORATION | 2019-11-21 | — | — | US | disclosed |
| EP-2937345-B1 | TYPE II RAF KINASE INHIBITORS | DANA FARBER CANCER INST INC (US) | 2018-03-21 | — | — | EP | disclosed |
| US-9358231-B2 | Type II RAF kinase inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| WO-2016077595-A1 | METHODS FOR TREATING NEURODEGENERATIVE DISEASES | THE GENERAL HOSPITAL CORPORATION (US) | 2016-05-19 | — | — | WO | disclosed |
| US-20160046636-A1 | TYPE II RAF KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-02-18 | — | — | US | disclosed |
| US-9180127-B2 | Type II Raf kinase inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| EP-2937345-A2 | Type II raf kinase inhibitors | Dana-Farber Cancer Institute, Inc. (US) | 2015-10-28 | — | — | EP | disclosed |
| US-20150157629-A1 | TYPE II RAF KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-06-11 | — | — | US | disclosed |
| EP-2519517-B1 | TYPE II RAF KINASE INHIBITORS | DANA FARBER CANCER INST INC (US) | 2015-03-25 | — | — | EP | disclosed |
| US-20130040949-A1 | TYPE II RAF KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-02-14 | — | — | US | disclosed |
| EP-2519517-A2 | TYPE II RAF KINASE INHIBITORS | Dana-Farber Cancer Institute, Inc. (US) | 2012-11-07 | — | — | EP | disclosed |
| WO-2011090738-A2 | TYPE II RAF KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2011-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11459570-B2 | Transgenic mouse expressing amyloid precursor protein that has olfactory neuron degeneration | APP, PSEN1, PSEN2 | MAPK14 2818/4885MAP3K7 3909/4885MAP4K2 4096/4885 |
| US-20190352643-A1 | METHODS FOR TREATING NEURODEGENERATIVE DISEASES | PSEN2, NLN, HTT | MAPK14 3032/4885MAP3K7 2977/4885MAP4K2 2519/4885 |
| US-11826365-B2 | Type II raf kinase inhibitors | BRAF, RAF1, ARAF | MAPK14 182/4885MAP3K7 21/4885MAP4K2 24/4885 |
| US-20150157629-A1 | TYPE II RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | MAPK14 182/4885MAP3K7 21/4885MAP4K2 24/4885 |
| US-20200297721-A1 | TYPE II RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | MAPK14 182/4885MAP3K7 21/4885MAP4K2 24/4885 |
| US-20160046636-A1 | TYPE II RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | MAPK14 182/4885MAP3K7 21/4885MAP4K2 24/4885 |
| US-20130040949-A1 | TYPE II RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | MAPK14 182/4885MAP3K7 21/4885MAP4K2 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.